INSTAGE: A 24-week, Double-blind, Randomized, Parallel-group Study Evaluating the Efficacy and Safety of Oral Nintedanib Co-administered With Oral Sildenafil, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Advanced Lung Function Impairment

Trial Profile

INSTAGE: A 24-week, Double-blind, Randomized, Parallel-group Study Evaluating the Efficacy and Safety of Oral Nintedanib Co-administered With Oral Sildenafil, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Advanced Lung Function Impairment

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Nintedanib (Primary) ; Sildenafil
  • Indications Idiopathic pulmonary fibrosis; Lung disorders
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 20 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 14 Nov 2017 Planned End Date changed from 15 Mar 2018 to 19 Apr 2018.
    • 17 Oct 2017 Planned End Date changed from 14 May 2018 to 15 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top